Roche has appointed Pamela Carroll as its new Global Head of Pathways Biology within in Pharmaceutical Research and Early Development unit.
She will also act as oncology discovery site head at the company’s research facility in Nutley, New Jersey.
Mike Burgess, Global Head Oncology, Discovery and Translational Area, and head, large molecule research at Roche, says Pam “has built a reputation for scientific excellence and leadership in the field”.
She first entered the pharmaceutical industry in 1999 with Bristol-Myers Squibb before joining Merck. Two years ago, she moved to the Belfer Institute of Applied Cancer Sciences at Dana Farber Cancer Institute, Harvard Medical School.
“Her broad knowledge and successful history in leading oncology drug discovery efforts make her is an ideal fit for this position,” Mr Burgess added.